参仙升脉口服液治疗缓慢性心律失常有效性和安全性的Meta分析  

Shenxianshengmai Oral Liquid for slow arrhythmia:a Meta analysis and systematic review

作　　者：郭雪娅[1] 魏涛涛[1] 张贵斌[1] 祁玉璟[1] 

机构地区：[1]兰州大学第二医院心内科,兰州730030

出　　处：《临床心血管病杂志》2016年第3期228-233,共6页Journal of Clinical Cardiology

基　　金：甘肃省自然科学基金(No:1208RJZA218)

摘　　要：目的:探讨参仙升脉口服液治疗缓慢性心律失常的有效性和安全性。方法:计算机检索Cochrane library(截止2015年第7期)、PubMed、Web of Science、中国知网、重庆维普、中华医学会数字化期刊、中国生物医学文献数据库、万方数据库,检索截止时间为2015年7月。两位研究员独立进行文献的筛选和资料的提取,采用Cochrane协作网推荐的Cochrane Handbook for Systematic Reviews of Interventions(5.1.0)进行质量评价。采用RevMan 5.3软件进行统计学分析。结果:总共纳入32个随机对照试验,包括2 483例缓慢性心律失常患者。共有6个研究报道了随机序列产生的方法。Meta分析结果提示:参仙升脉口服液能够提高平均心率[MD=6.80,95%CI(5.75,7.86),P<0.000 01],总有效率[OR=3.96,95%CI(3.10,5.07),P<0.000 01],并且参仙升脉口服液的不良反应发生率较低[OR=0.36,95%CI(0.20,0.64),P=0.006]。结论:参仙升脉口服液能够提高缓慢性心律失常患者的心率,并且明显改善患者的临床症状。Objective：To evaluate effectiveness and safety of Shenxianshengmai Oral Liquid for slow arrhythmia.Method：Cochrane library（issue 7,2015）,PubMed,Web of Science,CNKI,VIP,CMA Digital Periodicals,CBM and Wanfang database were searched for relevant iterms（up to Jul.2015）.Two reviewers selected studies and extracted data independently,and Cochrane Handbook for Systematic Reviews of Interventions（5.1.0）was used for quality assessment.Data statistical analysis was carried out using RevMan 5.3.Result：A total of 32 studies meeting the inclusion criteria,including 2483 participants.Six studies reported Random Sequence Generation.Result of meta-analysis indicated Shenxianshengmai Oral Liquid could increase average heart rate[MD=6.80,95%CI（5.75,7.86）,P〈0.000 01],total effectiveness[OR=3.96,95%CI（3.10,5.07）,P〈0.000 01],with lower adverse event[OR=0.36,95%CI（0.20,0.64）,P=0.006].Conclusion：Shenxianshengmai Oral Liquid shows more advantages for treatment of slow arrhythmia,and this results would be used to clinic prudently for limitation of included studies.

关 键 词：参仙升脉口服液 心律失常 缓慢性 META分析 

分 类 号：R541.7[医药卫生—心血管疾病]